Cargando…

Role of Anti-B-Cell Maturation Antigen (BCMA) in the Management of Multiple Myeloma

SIMPLE SUMMARY: Multiple myeloma is the most prevalent hematological cancer, and further treatments for this disease are required. Despite progress in the development of treatment regimens, multiple myeloma is still an incurable disease because of its poor response to therapy and high rate of resist...

Descripción completa

Detalles Bibliográficos
Autores principales: Rinaldi, Ikhwan, Muthalib, Abdul, Edina, Brenda Cristie, Wiyono, Lowilius, Winston, Kevin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9317279/
https://www.ncbi.nlm.nih.gov/pubmed/35884566
http://dx.doi.org/10.3390/cancers14143507
_version_ 1784755016695808000
author Rinaldi, Ikhwan
Muthalib, Abdul
Edina, Brenda Cristie
Wiyono, Lowilius
Winston, Kevin
author_facet Rinaldi, Ikhwan
Muthalib, Abdul
Edina, Brenda Cristie
Wiyono, Lowilius
Winston, Kevin
author_sort Rinaldi, Ikhwan
collection PubMed
description SIMPLE SUMMARY: Multiple myeloma is the most prevalent hematological cancer, and further treatments for this disease are required. Despite progress in the development of treatment regimens, multiple myeloma is still an incurable disease because of its poor response to therapy and high rate of resistance to treatment. However, anti-BCMA (B-cell maturation antigen) has shown promise in the treatment of multiple myeloma, and it may have the potential to be a new first-line treatment for patients. Thus, in this review, we objectively discussed the treatment potential of anti-BCMA, its mechanisms, and its future clinical implications for multiple myeloma patients. ABSTRACT: Over the past few decades, treatment options have become more advanced for multiple myeloma (MM), one of the most prevalent hematological cancers; however, multiple myeloma remains an incurable disease due to its poor response to therapy and high rates of resistance, which cause relapsed/refractory or multiple myeloma. Researchers have described anti-BCMA (B-cell maturation antigen) as a promising treatment regimen that targets the BCMA biomarker in the affected plasma cells. BCMA is a protein that is specifically expressed in plasma-cell neoplasms by using several mechanisms, such as CAR T cells (Chimeric Antigen Receptor T cells), antibody-drug conjugates, and bispecific T-cell engagers, thus allowing for a rapid response in the treatment of resistant or relapsed/refractory multiple myeloma patients. Anti-BCMA treatment is novel and specific in its mechanisms of action, with noninferior complete responses, higher overall survival rates, and fewer reported adverse events compared to other currently available treatment of MM. In this review, we compared anti-BCMA mechanisms with those of previously available therapies, such as those using immunomodulators and proteasome inhibitors, and discussed the advantages of using anti-BCMA as a potential first-line treatment for multiple myeloma patients.
format Online
Article
Text
id pubmed-9317279
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93172792022-07-27 Role of Anti-B-Cell Maturation Antigen (BCMA) in the Management of Multiple Myeloma Rinaldi, Ikhwan Muthalib, Abdul Edina, Brenda Cristie Wiyono, Lowilius Winston, Kevin Cancers (Basel) Review SIMPLE SUMMARY: Multiple myeloma is the most prevalent hematological cancer, and further treatments for this disease are required. Despite progress in the development of treatment regimens, multiple myeloma is still an incurable disease because of its poor response to therapy and high rate of resistance to treatment. However, anti-BCMA (B-cell maturation antigen) has shown promise in the treatment of multiple myeloma, and it may have the potential to be a new first-line treatment for patients. Thus, in this review, we objectively discussed the treatment potential of anti-BCMA, its mechanisms, and its future clinical implications for multiple myeloma patients. ABSTRACT: Over the past few decades, treatment options have become more advanced for multiple myeloma (MM), one of the most prevalent hematological cancers; however, multiple myeloma remains an incurable disease due to its poor response to therapy and high rates of resistance, which cause relapsed/refractory or multiple myeloma. Researchers have described anti-BCMA (B-cell maturation antigen) as a promising treatment regimen that targets the BCMA biomarker in the affected plasma cells. BCMA is a protein that is specifically expressed in plasma-cell neoplasms by using several mechanisms, such as CAR T cells (Chimeric Antigen Receptor T cells), antibody-drug conjugates, and bispecific T-cell engagers, thus allowing for a rapid response in the treatment of resistant or relapsed/refractory multiple myeloma patients. Anti-BCMA treatment is novel and specific in its mechanisms of action, with noninferior complete responses, higher overall survival rates, and fewer reported adverse events compared to other currently available treatment of MM. In this review, we compared anti-BCMA mechanisms with those of previously available therapies, such as those using immunomodulators and proteasome inhibitors, and discussed the advantages of using anti-BCMA as a potential first-line treatment for multiple myeloma patients. MDPI 2022-07-19 /pmc/articles/PMC9317279/ /pubmed/35884566 http://dx.doi.org/10.3390/cancers14143507 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Rinaldi, Ikhwan
Muthalib, Abdul
Edina, Brenda Cristie
Wiyono, Lowilius
Winston, Kevin
Role of Anti-B-Cell Maturation Antigen (BCMA) in the Management of Multiple Myeloma
title Role of Anti-B-Cell Maturation Antigen (BCMA) in the Management of Multiple Myeloma
title_full Role of Anti-B-Cell Maturation Antigen (BCMA) in the Management of Multiple Myeloma
title_fullStr Role of Anti-B-Cell Maturation Antigen (BCMA) in the Management of Multiple Myeloma
title_full_unstemmed Role of Anti-B-Cell Maturation Antigen (BCMA) in the Management of Multiple Myeloma
title_short Role of Anti-B-Cell Maturation Antigen (BCMA) in the Management of Multiple Myeloma
title_sort role of anti-b-cell maturation antigen (bcma) in the management of multiple myeloma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9317279/
https://www.ncbi.nlm.nih.gov/pubmed/35884566
http://dx.doi.org/10.3390/cancers14143507
work_keys_str_mv AT rinaldiikhwan roleofantibcellmaturationantigenbcmainthemanagementofmultiplemyeloma
AT muthalibabdul roleofantibcellmaturationantigenbcmainthemanagementofmultiplemyeloma
AT edinabrendacristie roleofantibcellmaturationantigenbcmainthemanagementofmultiplemyeloma
AT wiyonolowilius roleofantibcellmaturationantigenbcmainthemanagementofmultiplemyeloma
AT winstonkevin roleofantibcellmaturationantigenbcmainthemanagementofmultiplemyeloma